Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19

Writing Committee for the REMAP-CAP Investigators, The; C. Angus, Derek; Derde, Lennie; Al-Beidh, Farah; Annane, Djillali; Arabi, Yaseen; Beane, Abigail; van Bentum-Puijk, Wilma; Berry, Lindsay; Bhimani, Zahra; Bonten, Marc; Bradbury, Charlotte; Brunkhorst, Frank; Buxton, Meredith; Buzgau, Adrian; C. Cheng, Allen; de Jong, Menno; Detry, Michelle; Estcourt, Lise; Fitzgerald, Mark; Goossens, Herman; Green, Cameron; Haniffa, Rashan; M. Higgins, Alisa; Horvat, Christopher; J. Hullegie, Sebastiaan; Kruger, Peter; Lamontagne, Francois; R. Lawler, Patrick; Linstrum, Kelsey; Litton, Edward; Lorenzi, Elizabeth; Marshall, John; McAuley, Daniel; McGlothin, Anna; McGuinness, Shay; McVerry, Bryan; Montgomery, Stephanie; Mouncey, Paul; Murthy, Srinivas; Nichol, Alistair; Parke, Rachael; Parker, Jane; Rowan, Kathryn; Sanil, Ashish; Santos, Marlene; Saunders, Christina; Seymour, Christopher; Turner, Anne; van de Veerdonk, Frank; Venkatesh, Balasubramanian; Zarychanski, Ryan; Berry, Scott; J. Lewis, Roger; McArthur, Colin; A. Webb, Steven; C. Gordon, Anthony

doi:10.1001/jama.2020.17022

Public

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Shared by NobleBlocks on Sep 2, 2020 • 12:00 AM UTC

Authors:

D. Angus

L. Derde

Farah Al-Beidh

Abstract

Importance Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants An ongoing adaptive platform trial testing multiple interven...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!